These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37961238)

  • 21. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
    Lakshman A; Rajkumar SV; Buadi FK; Binder M; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Cancer J; 2018 Jun; 8(6):59. PubMed ID: 29895887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastrointestinal amyloidosis in a patient with smoldering multiple myeloma: A case report.
    Liu AL; Ding XL; Liu H; Zhao WJ; Jing X; Zhou X; Mao T; Tian ZB; Wu J
    World J Clin Cases; 2022 Mar; 10(7):2307-2314. PubMed ID: 35321167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolving diagnostic criteria for multiple myeloma.
    Rajkumar SV
    Hematology Am Soc Hematol Educ Program; 2015; 2015():272-8. PubMed ID: 26637733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The consultant's guide to smoldering multiple myeloma.
    Thorsteinsdottir S; Kristinsson SY
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):551-559. PubMed ID: 36485144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
    Kazandjian D; Hill E; Dew A; Morrison C; Roswarski J; Korde N; Emanuel M; Petrosyan A; Bhutani M; Calvo KR; Dulau-Florea A; Kwok M; Lee MJ; Lee S; Lindenberg L; Mailankody S; Manasanch E; Maric I; Mena E; Patel N; Tageja N; Trepel JB; Turkbey B; Wang HW; Wang W; Yuan C; Zhang Y; Braylan R; Choyke P; Stetler-Stevenson M; Steinberg SM; Figg WD; Roschewski M; Landgren O
    JAMA Oncol; 2021 Nov; 7(11):1678-1685. PubMed ID: 34529025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
    Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
    Front Immunol; 2021; 12():792609. PubMed ID: 34880879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
    Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
    Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.
    Sandecka V; Popkova T; Stork M; Maisnar V; Minarik J; Jungova A; Pavlicek P; Stejskal L; Pospisilova L; Heindorfer A; Obernauerova J; Gregora E; Sykora M; Ullrychova J; Wrobel M; Kessler P; Jelinek T; Kunovszki P; Bathija S; Gros B; Wilbertz S; Cai Q; Lam A; Spicka I
    Blood Cancer J; 2023 Sep; 13(1):153. PubMed ID: 37752128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Smoldering, asymptomatic stage 1, and indolent myeloma.
    Greipp PR
    Curr Treat Options Oncol; 2000 Jun; 1(2):119-26. PubMed ID: 12057049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone Tumors: Multiple Myeloma.
    Kane SF
    FP Essent; 2020 Jun; 493():30-35. PubMed ID: 32573185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.
    Bladé J; Dimopoulos M; Rosiñol L; Rajkumar SV; Kyle RA
    J Clin Oncol; 2010 Feb; 28(4):690-7. PubMed ID: 20026810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
    Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M
    Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New approaches to smoldering myeloma.
    Mateos MV; San Miguel JF
    Curr Hematol Malig Rep; 2013 Dec; 8(4):270-6. PubMed ID: 23975678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies.
    Kazandjian D; Mailankody S; Korde N; Landgren O
    Clin Adv Hematol Oncol; 2014 Sep; 12(9):578-87. PubMed ID: 25654479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-risk smoldering myeloma: Perspective on watchful monitoring.
    Leng S; Lentzsch S
    Semin Oncol; 2016 Dec; 43(6):697-699. PubMed ID: 28061989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; Rajkumar SV
    Curr Hematol Malig Rep; 2010 Apr; 5(2):62-9. PubMed ID: 20425398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular imaging in myeloma precursor disease.
    Mena E; Choyke P; Tan E; Landgren O; Kurdziel K
    Semin Hematol; 2011 Jan; 48(1):22-31. PubMed ID: 21232655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How I approach smoldering multiple myeloma.
    Vaxman I; Gertz MA
    Blood; 2022 Aug; 140(8):828-838. PubMed ID: 35576526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.